M. abscessus Biobank: Advancing Personalized Phage Therapy
Help Us Build the Future of Personalized Treatment for Mycobacterium abscessus Infections
Tolka AI Therapeutics is conducting an IRB-approved research study to establish a patient-focused biobank for Mycobacterium abscessus (Mab) respiratory isolates.
Your contribution could lead to the development of personalized bacteriophage therapy — a promising alternative for antibiotic-resistant infections.
Quick Eligibility Check
- ✅ 18 years or older
- ✅ Resident of the United States
- ✅ Mab isolated from respiratory specimens
- ✅ Able to produce sputum samples
How It Works
- Sign Up – Provide your email and review eligibility
- Consent – Complete electronic informed consent
- Receive Kit – Get your home collection kit (no cost)
- Collect Samples – Two morning sputum samples
- Ship Back – Use the provided prepaid shipping materials
- Stay Connected – Receive updates if phages are found
Your Privacy Matters
- All samples are de-identified
- Secure storage at our Miami laboratory
- No sharing without your permission
- You have the right to withdraw at any time
Potential Future Benefits
If we identify bacteriophages active against your Mab isolate, you’ll be notified about opportunities to participate in:
- Expanded access programs
- Clinical trials
- Personalized phage therapy research
IRB Approval:
BRANY IRB Study #25-08-468-1945